What is the appropriate diagnosis and treatment plan for a young adult female who presented after an intentional overdose of hydroxyzine and sertraline, with a history of borderline personality disorder, major depressive disorder, generalized anxiety disorder, recent daily alcohol and THC use, and who is currently agitated, refusing food, and non‑participatory?

Diagnosis and Treatment for Intentional Overdose with Sertraline and Hydroxyzine in a Patient with Borderline Personality Disorder

This patient requires immediate medical stabilization for potential serotonin syndrome, followed by psychiatric hospitalization with dialectical behavior therapy (DBT) as the primary treatment, while carefully discontinuing or minimizing psychotropic medications that pose overdose risk.

Immediate Medical Management

Assess for Serotonin Syndrome

The combination of 20 tablets of sertraline (an SSRI) with hydroxyzine creates risk for serotonin syndrome, particularly given the patient's agitation, pressured speech, and altered mental status 1. Monitor specifically for the clinical triad: mental status changes (agitation, confusion), autonomic hyperactivity (tachycardia, diaphoresis, hyperthermia), and neuromuscular abnormalities (tremor, hyperreflexia, clonus, muscle rigidity) 1, 2.

Apply the Hunter Criteria for diagnosis: Has the patient taken a serotonergic drug AND does she exhibit spontaneous clonus, inducible clonus with agitation/diaphoresis, ocular clonus with agitation/diaphoresis, tremor with hyperreflexia, or muscle rigidity with temperature >38°C plus clonus? 1

If serotonin syndrome is present:

• Discontinue all serotonergic agents immediately 2, 3
• Provide supportive care: IV fluids, benzodiazepines for agitation (avoid physical restraints as they worsen hyperthermia and lactic acidosis) 1
• Monitor for severe complications: hyperthermia >41.1°C, rhabdomyolysis, metabolic acidosis, renal failure, seizures 1
• Consider cyproheptadine (serotonin antagonist) for severe cases 1

Overdose Management

For sertraline overdose: The clinical presentation is typically mild with isolated ingestion 4. Common findings include tremor, lethargy, nausea, agitation, and confusion 4. Deaths have been reported with very large ingestions despite SSRIs having better safety margins than older antidepressants 2.

For hydroxyzine overdose: Expect hypersedation as the primary manifestation 5. Monitor for QT prolongation and Torsade de Pointes with ECG 5. There is no specific antidote 5.

Treatment approach:

• Supportive care with frequent vital sign monitoring 5
• Activated charcoal if within appropriate timeframe
• IV fluids for hypotension 5
• Continuous cardiac monitoring for QT prolongation 5
• Avoid epinephrine (hydroxyzine counteracts its pressor action) 5

Manage Acute Agitation

The patient's agitation, pressured speech, and flight of ideas in the ED require immediate intervention. Use benzodiazepines (lorazepam 2-4 mg) as first-line monotherapy for acute agitation 6. This is preferable to antipsychotics given the overdose context and need to avoid additional serotonergic or anticholinergic effects 6.

Prioritize verbal de-escalation before chemical restraint: maintain calm demeanor, respect personal space, avoid confrontation, listen actively, and provide clear options 7.

Psychiatric Diagnosis

Primary Diagnosis: Borderline Personality Disorder

The collateral history strongly supports BPD:

• Chronic pattern of unstable relationships (conflict over 37-year-old partner, family disapproval)
• Recurrent suicidal behavior and self-harm (intentional overdose, stating "wanted to die, period")
• Affective instability and emotional dysregulation
• Impulsivity (21 days of daily alcohol use, THC use, medication noncompliance)
• Inconsistent self-reporting and splitting behaviors 8, 9

Comorbid Conditions

• Major Depressive Disorder (per collateral history of depression, suicidal ideation)
• Generalized Anxiety Disorder (per collateral history)
• Substance Use Disorder (recent daily alcohol use × 21 days, THC use)

Critical consideration: The pressured speech, flight of ideas, and agitation raise concern for either:

1. Behavioral activation from SSRI treatment (more likely given recent medication noncompliance followed by overdose) 2
2. Emerging manic/hypomanic episode suggesting possible bipolar disorder 3
3. Serotonin syndrome manifestations 1, 2

Definitive Treatment Plan

Psychotherapy: The Primary Treatment

Dialectical Behavior Therapy (DBT) is the evidence-based first-line treatment for BPD and should be initiated as soon as the patient is medically stable 10. DBT has demonstrated efficacy in reducing both suicidal and non-suicidal self-directed violence in patients with BPD 10. It combines CBT elements, skills training, and mindfulness to develop emotion regulation, interpersonal effectiveness, and distress tolerance 10.

Crisis Response Plan: Develop a collaborative crisis response plan that includes 10:

• Identification of clear warning signs (behavioral, cognitive, affective, physical)
• Self-management skills and distraction techniques
• Social support contacts (friends, family who have helped previously)
• Professional resources and emergency contacts

Pharmacotherapy: Minimize and Target Comorbidities Only

The fundamental principle: Psychosocial treatment, not drugs, is first-line management for BPD 9, 11. Medications should only be adjunctive to psychotherapy 8, 9.

Major Prescribing Hazards to Avoid:

1. Polypharmacy - This patient was prescribed sertraline and likely other medications; 35% of BPD patients are prescribed ≥3 psychotropics, often off-label 12, 8
2. Overdose risk - 58% of medications taken in BPD overdoses are prescribed agents 12. Quetiapine is particularly over-represented in both off-label prescribing and associated harm 12
3. Medication misuse 9

Specific Medication Recommendations:

Discontinue or minimize current medications:

• Reassess sertraline necessity: SSRIs have limited evidence for BPD core symptoms 11. They may be warranted only if comorbid MDD persists after acute stabilization 8, 9, 13. If continued, monitor closely for behavioral activation (restlessness, impulsivity, disinhibition) which is more common in younger patients and anxiety disorders 2
• Avoid benzodiazepines for chronic use - Despite being commonly prescribed, they pose significant overdose risk, especially when combined with alcohol 12
• Avoid antipsychotics unless psychosis present - No clear evidence for BPD treatment; quetiapine particularly associated with overdose harm 12, 11

If pharmacotherapy is deemed necessary for comorbid depression:

• Use single medications in limited quantities for limited time 9
• Set clear, collaborative goals reviewed regularly 9
• Stop ineffective drugs promptly 9
• Prescribe only 1-week supplies initially given suicide risk
• Consider mood stabilizers (valproate, lamotrigine) which have some supportive evidence for affective symptoms in BPD 11

For substance use disorder:

• Address alcohol and THC use through integrated treatment
• Consider that substance use may be self-medication for emotional dysregulation

Safety Planning and Disposition

Psychiatric hospitalization is indicated given:

• Recent serious suicide attempt with clear intent ("wanted to die, period")
• Current refusal to engage or eat
• Inability to assess mental status due to non-participation
• Need for medication washout and observation
• Requirement for intensive DBT initiation

During hospitalization:

• Complete medical clearance with serial assessments for delayed toxicity
• Comprehensive psychiatric evaluation when patient able to participate
• Screen for bipolar disorder given pressured speech and flight of ideas 3
• Initiate DBT skills training
• Involve family/collateral sources in treatment planning (with patient consent)
• Address interpersonal stressors (relationship conflict, childcare concerns)
• Establish outpatient DBT program before discharge

Monitoring and Follow-up

Close monitoring required for:

• Suicidality (especially in first months if antidepressant continued) 2
• Behavioral activation/agitation if SSRI restarted 2
• Substance use relapse
• Medication adherence
• Engagement with DBT

Common pitfall: Treating BPD primarily with medications leads to polypharmacy, overdose risk, and neglect of evidence-based psychotherapy 8, 9, 11. The patient's 6-month medication noncompliance suggests medications were not addressing core issues.

Key principle: BPD core symptoms (chronic emptiness, identity disturbance, abandonment fears) are not significantly influenced by any drug 11. Focus treatment on DBT while minimizing pharmacological interventions to only those targeting specific comorbid conditions with clear treatment goals.